Sipuleucel‐T, a DC vaccine that uses recombinant fusion protein antigens such as prostatic acid phosphatase (PAP) and GM‐CSF, is currently the only clinically approved DC vaccine for the treatment of prostate cancer.[64] Studies have shown that it can stimulate a systemic immune response when infused in patients with metastatic castration‐resistant prostate cancer (mCRPC).[65] Other clinical trials have investigated the combination use of DC vaccines with chemotherapy or immune checkpoint inhibitors.[66]. This evidence concerns the gene ACP3 and prostate carcinoma.